<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Beta blocker poisoning</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Beta blocker poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Beta blocker poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fermin Barrueto, Jr, MD, MBA, FACHE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Stolbach, MD, MPH, FAACT, FACMT, FACEP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Grayzel, MD, FAAEM</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Beta adrenergic antagonists (beta blockers) have been in clinical use for more than 30 years and are employed in the management of a range of disorders, including hypertension, ischemic heart disease, heart failure, arrhythmias, migraine headache, tremor, portal hypertension, and aortic dissection.</p><p>Although safe for most patients when taken as prescribed, beta blocker toxicity is associated with significant morbidity and mortality [<a href="#rid1">1</a>]. A 10-year review (2006 to 2015) of "double-dose" ingestions from the California Poison Control System revealed that antihypertensives like beta-blockers and calcium channel blockers caused moderate to severe effects in 37 percent of cases. For comparison, the second drug class with moderate to severe effects were stimulants at 17 percent [<a href="#rid2">2</a>].</p><p>The presentation, diagnosis, and management of beta blocker poisoning is reviewed here. A summary table to facilitate emergency management is provided  (<a class="graphic graphic_table graphicRef82572" href="/d/graphic/82572.html" rel="external">table 1</a>). A general approach to an adult patient with possible drug intoxication, and an overview of adverse effects of beta blockade, are discussed separately. (See  <a class="medical medical_review" href="/d/html/967.html" rel="external">"Major side effects of beta blockers"</a> and  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a> and  <a class="medical medical_review" href="/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGY</span></p><p class="headingAnchor" id="H3"><span class="h2">Receptor types and general mechanism</span><span class="headingEndMark"> — </span>There are at least three distinct types of beta receptors:</p><p class="bulletIndent1"><span class="glyph">●</span>Beta 1, which are found primarily in heart muscle. Activation of these receptors results in an increase in heart rate, contractility, atrioventricular (AV) conduction, and a decrease in AV node refractoriness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beta 2, which are present in heart muscle but are more prominent in bronchial and peripheral vascular smooth muscle. Activation of these receptors results in vasodilation and bronchodilation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beta 3, which are found in adipose tissue and the heart. Activation of these receptors may mediate catecholamine-induced thermogenesis and may reduce cardiac contractility.</p><p></p><p>Competitive antagonism of the beta receptor decreases cellular levels of cyclic adenosine monophosphate (cAMP). Beta-1 selective blockade results in depressed myocardial contractility, decreased automaticity in pacemaker cells, and decreased conduction velocity through the atrioventricular node [<a href="#rid3">3</a>]. The lungs, peripheral blood vessels, glucose metabolism, and central nervous system are all affected by beta blockade. Nonselective beta blockade results in systemic effects including bronchoconstriction, impaired gluconeogenesis, and decreased insulin release. (See  <a class="medical medical_review" href="/d/html/967.html" rel="external">"Major side effects of beta blockers"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">CELLULAR TOXICOLOGY</span><span class="headingEndMark"> — </span>There are many beta blockers available for clinical use, and although they all inhibit the beta-adrenoreceptor, there are several characteristics that differ among these agents. Following overdose, manifestations of toxicity are observed in varying degrees, depending on the specific agent and dose involved [<a href="#rid3">3,4</a>]. In addition to beta-adrenoreceptor blockade, three properties that affect toxicity include the membrane stabilizing activity (MSA), lipophilicity, and intrinsic sympathomimetic activity (ISA) of the ingested agent  (<a class="graphic graphic_table graphicRef82571" href="/d/graphic/82571.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Membrane stabilizing activity (MSA) – Membrane stabilizing agents (eg, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, <a class="drug drug_general" data-topicid="9233" href="/d/drug information/9233.html" rel="external">acebutolol</a>) inhibit myocardial fast sodium channels, which can result in a widened QRS interval and may potentiate other dysrhythmias.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lipophilicity – Beta blockers with high lipid solubility (eg, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>) rapidly cross the blood brain barrier into the central nervous system, predisposing to neurologic sequelae such as seizures and delirium. Beta Blockers with this characteristic are more amenable to treatment with 20 percent lipid emulsion therapy in the setting of a clinically significant overdose [<a href="#rid5">5</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intrinsic sympathomimetic activity (ISA) – Many agents demonstrate a partial agonist effect at the beta receptor site, resulting in less bradycardia and hypotension in therapeutic and supratherapeutic doses. Bronchoconstriction is also less likely to occur with compounds that possess intrinsic sympathomimetic activity (ISA), or beta-1 selectivity. However, the protective effects of ISA do not completely prevent cardiovascular toxicity following intentional or accidental overdose.</p><p></p><p class="headingAnchor" id="H5"><span class="h1">TOXICITY OF GENERAL CLASS AND SPECIFIC DRUGS</span><span class="headingEndMark"> — </span>Complications following beta blocker overdose are related to excessive beta adrenergic blockade, and occasionally the proarrhythmic (membrane-stabilizing) activity of these agents on cardiac conduction [<a href="#rid6">6</a>]. Ingestion of other cardioactive agents in association with beta blockers increases mortality following overdose [<a href="#rid3">3,6</a>]. Common and potentially dangerous coingestions include calcium channel blockers, cyclic antidepressants, and neuroleptics [<a href="#rid6">6</a>].</p><p>Of all the variables contributing to toxicity, membrane stabilizing activity (MSA) appears to have the greatest influence on adverse cardiovascular effects  (<a class="graphic graphic_table graphicRef82571" href="/d/graphic/82571.html" rel="external">table 2</a>). Agents with significant MSA include <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, <a class="drug drug_general" data-topicid="9233" href="/d/drug information/9233.html" rel="external">acebutolol</a>, <a class="drug drug_general" data-topicid="9145" href="/d/drug information/9145.html" rel="external">betaxolol</a>, and oxprenolol. The effect of MSA is thought to be negligible at therapeutic doses, but in overdose can cause significant cardiovascular morbidity. In one retrospective study, 94 percent (15 out of 16) of patients with cardiovascular toxicity had a history of ingesting beta blockers with MSA [<a href="#rid6">6</a>].</p><p><a class="drug drug_general" data-topicid="9233" href="/d/drug information/9233.html" rel="external">Acebutolol</a>, a cardioselective agent with partial agonist activity and significant MSA, is one of the most toxic beta blockers in overdose [<a href="#rid7">7</a>]. Acebutolol toxicity may predispose the patient to ventricular repolarization resulting in arrhythmias [<a href="#rid7">7</a>].</p><p><a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">Sotalol</a> combines class III antidysrhythmic properties with beta adrenergic antagonism. Sotalol prolongs the action potential duration and increases the refractory period by blocking delayed potassium channels. This leads to prolongation of the QTc interval, and can contribute to the development of Torsades de Pointes [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/925.html" rel="external">"Clinical uses of sotalol"</a> and  <a class="medical medical_review" href="/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p><a class="drug drug_general" data-topicid="9208" href="/d/drug information/9208.html" rel="external">Carvedilol</a> has been associated with toxic epidermal necrolysis at therapeutic levels [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H6"><span class="h1">PHARMACOKINETICS</span><span class="headingEndMark"> — </span>In therapeutic use, most beta blockers have half-lives ranging from two to eight hours, but kinetics can change in overdose  (<a class="graphic graphic_table graphicRef82571" href="/d/graphic/82571.html" rel="external">table 2</a>). Ingestion of sustained release preparations can delay the onset of symptoms and substantially prolong the duration of toxicity.</p><p>Many beta blockers are metabolized via the liver. <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">Esmolol</a> is metabolized by erythrocyte esterases. <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">Atenolol</a>, <a class="drug drug_general" data-topicid="9158" href="/d/drug information/9158.html" rel="external">bisoprolol</a>, <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a>, and <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">sotalol</a> are eliminated by the kidney.</p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL FEATURES OF OVERDOSE</span><span class="headingEndMark"> — </span>Diagnosis of beta blocker intoxication is made on the basis of history and clinical presentation.</p><p class="headingAnchor" id="H9"><span class="h2">History</span><span class="headingEndMark"> — </span>Data obtained should include the specific agent, amount ingested, time of ingestion, and any coingestions. Historical features that suggest increased risk for severe toxicity include:</p><p class="bulletIndent1"><span class="glyph">●</span>Coingestion of other cardioactive agents</p><p class="bulletIndent1"><span class="glyph">●</span>Underlying cardiac disease (eg, heart failure)</p><p class="bulletIndent1"><span class="glyph">●</span>Ingestion of <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">sotalol</a> or another agent with membrane-stabilizing activity (eg, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> or <a class="drug drug_general" data-topicid="9233" href="/d/drug information/9233.html" rel="external">acebutolol</a>) (see <a class="local">'Toxicity of general class and specific drugs'</a> above)</p><p></p><p>Any possible witnesses and emergency medical services (EMS) personnel who may have recovered pill bottles at the scene should be contacted. The patient's pharmacy may provide valuable information regarding prescribed medications, the date of the most recent refill, and the total number of pills dispensed.</p><p class="headingAnchor" id="H10"><span class="h2">Physical findings</span><span class="headingEndMark"> — </span>Most patients who overdose on beta blockers become symptomatic within two hours following ingestion, and nearly all develop symptoms within six hours [<a href="#rid6">6,10</a>]. Exceptions to this general rule include ingestions of sustained release medications and <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">sotalol</a> [<a href="#rid11">11</a>]. In these cases, delayed toxicity up to 24 hours after ingestion can occur. </p><p>Bradycardia and hypotension are the most common effects, and in severe overdoses can result in profound myocardial depression and cardiogenic shock. Ventricular dysrhythmias are seen more frequently following <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> and <a class="drug drug_general" data-topicid="9233" href="/d/drug information/9233.html" rel="external">acebutolol</a> exposures, probably because of the increased membrane-stabilizing activity (MSA) of these agents  (<a class="graphic graphic_table graphicRef82571" href="/d/graphic/82571.html" rel="external">table 2</a>) [<a href="#rid6">6,12</a>]. Other potential effects of severe toxicity include mental status change, seizure, hypoglycemia, and bronchospasm.</p><p>Mental status changes, including delirium, coma, and seizures, occur most frequently in patients with severe hypotension, but can occur in those with normal blood pressure [<a href="#rid13">13</a>]. Similarly, respiratory depression usually occurs in hypotensive, comatose patients, but has been reported in awake patients. Specific agents, particularly <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, are associated with neurologic effects in the absence of cerebral hypoperfusion. This was demonstrated in a report comparing the clinical course of patients following overdose with either propranolol or other beta blockers [<a href="#rid10">10</a>]. Although the minimum pulse and systolic and diastolic ranges were not significantly different between groups, 29 percent of the propranolol group experienced seizures versus none in the non-propranolol group. This difference is probably due to the increased lipophilicity of propranolol, allowing rapid diffusion into the central nervous system.</p><p>In addition to the cardiovascular and neurologic manifestations, bronchospasm and hypoglycemia can complicate acute beta blocker intoxication. Early recognition and prompt treatment of hypoglycemia is critical. (See <a class="local">'Management'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h1">LABORATORY EVALUATION</span></p><p class="headingAnchor" id="H12"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>Although serum concentrations of most beta blockers can be measured, they cannot be obtained in time to be clinically useful and are generally performed only for academic or forensic purposes.</p><p>In patients with beta blocker overdose, we generally obtain the following studies: an electrocardiogram (ECG), a fingerstick glucose, serum electrolytes including calcium, and blood urea nitrogen and creatinine levels. If calcium is administered repeatedly, levels should be measured every four to six hours. If an insulin/glucose treatment regimen is used, glucose and potassium levels must be measured every 30 to 60 minutes. (See <a class="local">'Insulin and glucose'</a> below and <a class="local">'Calcium'</a> below.)</p><p>Routine laboratory evaluation of any poisoned patient should include <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and salicylate levels, to rule out these common coingestions, and a pregnancy test in women of childbearing age. </p><p>A serum lactate concentration above 3 mmol/L is used to predict life-threatening overdose of some medications. However, this may be an insensitive finding with beta blocker overdose. In one retrospective study, four of nine deaths associated with beta blocker poisoning were associated with serum lactate concentrations below 3 mmol/L [<a href="#rid14">14</a>]. </p><p>Additional tests are obtained based upon clinical findings. As an example, a plain chest radiograph is obtained in patients with signs of pulmonary edema.</p><p class="headingAnchor" id="H13"><span class="h2">Electrocardiogram</span><span class="headingEndMark"> — </span>Beta blockers decrease conduction velocity across the atrioventricular (AV) node, resulting in PR prolongation  (<a class="graphic graphic_waveform graphicRef67882" href="/d/graphic/67882.html" rel="external">waveform 1</a>) and possibly AV block  (<a class="graphic graphic_waveform graphicRef53638" href="/d/graphic/53638.html" rel="external">waveform 2</a>); they also slow automaticity within the sinoatrial (SA) node, causing bradycardia  (<a class="graphic graphic_waveform graphicRef52675" href="/d/graphic/52675.html" rel="external">waveform 3</a>) [<a href="#rid15">15</a>].</p><p>QRS prolongation occurs more commonly when beta blockers with membrane stabilizing activity (MSA) are ingested. Significant QTc prolongation can develop following <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">sotalol</a> overdose as a result of its independent Class III antiarrhythmic activity. In severe poisoning, the electrocardiogram (ECG) can show <strong>ANY</strong> bradydysrhythmia, and can progress to asystole. (See  <a class="medical medical_review" href="/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults", section on 'Asystole and pulseless electrical activity'</a>.)</p><p>A Brugada-like ECG pattern  (<a class="graphic graphic_waveform graphicRef122897" href="/d/graphic/122897.html" rel="external">waveform 4</a>) has been reported in the setting of <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> poisoning, suggesting that other beta blockers that are lipophilic or possess membrane stabilizing activity might have similar effects [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H318752567"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of beta blocker poisoning is made clinically on the basis of the history and clinical presentation. Typically there is a history of overdose combined with findings of bradycardia and hypotension, which can be profound in severe overdose, resulting in cardiogenic shock. Other findings can include ventricular dysrhythmia, altered mental status, seizure, hypoglycemia, and bronchospasm. Although serum concentrations of most beta blockers can be measured, such measurements generally cannot be obtained in time to be clinically useful. </p><p class="headingAnchor" id="H56212731"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Many drugs can cause profound hypotension or bradydysrhythmia in overdose. Calcium channel blockers, <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>, <a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">clonidine</a>, and cholinergic agents must be considered when evaluating bradydysrhythmia potentially caused by a toxic ingestion.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium channel blocker poisoning</strong> ‒ Calcium channel blockers are less likely than beta blockers to produce alterations in mental status, and frequently do not do so unless the patient is in profound shock. Hyperglycemia occurs more often with calcium channel blocker toxicity, while beta blockers are associated with hypoglycemia. (See  <a class="medical medical_review" href="/d/html/331.html" rel="external">"Calcium channel blocker poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">Digoxin</a><strong> poisoning</strong> ‒ Nausea and vomiting occur more often with digoxin toxicity than beta blocker toxicity. Digoxin may cause characteristic changes in an electrocardiogram, such as scooped ST segment depressions  (<a class="graphic graphic_waveform graphicRef56737" href="/d/graphic/56737.html" rel="external">waveform 5</a>). Digoxin is more likely to produce rhythms of increased automaticity, such as atrial tachycardia with atrioventricular block, premature ventricular contractions, or ventricular arrhythmias. (See  <a class="medical medical_review" href="/d/html/319.html" rel="external">"Digitalis (cardiac glycoside) poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">Clonidine</a><strong> poisoning</strong> ‒ Clonidine produces a constellation of signs that can resemble opioid overdose, including somnolence and miosis, but are accompanied by hypotension and bradycardia. (See  <a class="medical medical_review" href="/d/html/6509.html" rel="external">"Clonidine, xylazine, and related imidazoline poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholinergic drug poisoning</strong> ‒ Overdose of a cholinergic agent can present with bradycardia but also includes other characteristic features (salivation, lacrimation, urination, defecation, GI upset, and muscle excitability)  (<a class="graphic graphic_table graphicRef71268" href="/d/graphic/71268.html" rel="external">table 3</a>).</p><p></p><p class="headingAnchor" id="H14"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H15"><span class="h2">Acute stabilization and overview of therapy</span></p><p class="headingAnchor" id="H3582624704"><span class="h3">Airway, breathing, circulation</span><span class="headingEndMark"> — </span>Management begins with assessment of the patient’s airway, breathing, and circulation. The airway is secured as necessary and adequate oxygenation ensure. Advanced cardiac life support is provided as necessary. A table summarizing emergency interventions is provided  (<a class="graphic graphic_table graphicRef82572" href="/d/graphic/82572.html" rel="external">table 1</a>). <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">Atropine</a> should be given early in bradycardic patients and whenever possible as a pretreatment agent when rapid sequence intubation is required [<a href="#rid17">17</a>]. Intravenous access should be obtained and continuous cardiac monitoring performed. (See  <a class="medical medical_review" href="/d/html/270.html" rel="external">"Rapid sequence intubation in adults for emergency medicine and critical care"</a> and  <a class="medical medical_review" href="/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults"</a>.)</p><p>Hypotension is treated initially with intravenous (IV) boluses of isotonic fluid; symptomatic bradycardia is treated with <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a>. Atropine is given in a dose of 0.5 to 1 mg every three to five minutes up to a total of 0.03 to 0.04 mg/kg. <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">Sodium bicarbonate</a> and magnesium may be needed to treat QRS prolongation and ventricular arrhythmia (torsade de pointe), respectively. (See <a class="local">'Other therapies'</a> below.)</p><p class="headingAnchor" id="H1226873674"><span class="h3">Hypoglycemia and seizures</span><span class="headingEndMark"> — </span>Symptomatic hypoglycemia is treated with <a class="drug drug_general" data-topicid="8711" href="/d/drug information/8711.html" rel="external">IV dextrose</a>. For adults, administer boluses of 50 percent dextrose in water (D50W); for children administer an appropriate IV bolus of dextrose (0.25 g/kg body weight). In infants and young children this is usually given as 2.5 mL/kg of 10 percent dextrose solution. Multiple doses of dextrose may be necessary. Treatment of hypoglycemia in children is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5805.html" rel="external">"Approach to hypoglycemia in infants and children"</a>.)</p><p>Treat seizures with benzodiazepines (eg, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>). (See  <a class="medical medical_review" href="/d/html/2217.html" rel="external">"Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3207583702"><span class="h3">Additional treatments</span><span class="headingEndMark"> — </span>IV fluid and <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a> often do not completely reverse the cardiotoxic effects of beta blocker overdose. In such cases, additional treatments are given based upon the severity of the presentation. These treatments may include:</p><p class="bulletIndent1"><span class="glyph">●</span>IV <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a></p><p class="bulletIndent1"><span class="glyph">●</span>IV calcium salts</p><p class="bulletIndent1"><span class="glyph">●</span>Vasopressor</p><p class="bulletIndent1"><span class="glyph">●</span>High dose insulin and glucose infusions</p><p class="bulletIndent1"><span class="glyph">●</span>Lipid emulsion therapy</p><p></p><p>These therapeutic options are discussed below. (See <a class="local">'Approach to the selection of specific therapies'</a> below.)</p><p>Hemodialysis may be needed in specific circumstances (eg, severely ill patient with ingestion of medication amenable to hemodialysis and not responding to medical therapy), although this is uncommon. In such cases a nephrologist should be contacted early in the patient’s course. (See <a class="local">'Other therapies'</a> below.)</p><p>Many patients with isolated beta blocker overdose remain asymptomatic and can be discharged after a period of observation. (See <a class="local">'Disposition'</a> below.)</p><p class="headingAnchor" id="H61484287"><span class="h2">Approach to the selection of specific therapies</span><span class="headingEndMark"> — </span>Although it is ideal to institute treatments individually to assess their success or failure, this is often not possible in patients who are severely ill from a beta blocker poisoning. Our suggested approaches to therapy based upon the severity of the clinical presentation are described here; a summary table to facilitate emergency management is provided  (<a class="graphic graphic_table graphicRef82572" href="/d/graphic/82572.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H61484294"><span class="h3">Severely symptomatic patients</span><span class="headingEndMark"> — </span>Our suggested approach to patients manifesting signs of severe beta blocker poisoning (profound hypotension and/or severe bradycardia, depressed mental status) consists of multiple <strong>simultaneous</strong> interventions, including <strong>all</strong> of the following treatments [<a href="#rid18">18-20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stabilization of the airway as necessary (avoid induction agents that exacerbate hypotension)</p><p class="bulletIndent1"><span class="glyph">●</span>Additional IV boluses of isotonic crystalloid</p><p class="bulletIndent1"><span class="glyph">●</span>IV <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a></p><p class="bulletIndent1"><span class="glyph">●</span>IV calcium salts</p><p class="bulletIndent1"><span class="glyph">●</span>IV vasopressor (eg, <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>IV high-dose insulin and glucose</p><p class="bulletIndent1"><span class="glyph">●</span>IV lipid emulsion therapy for poisoning involving lipophilic medications (eg, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a>, <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a>)</p><p></p><p>Vasopressor therapy is typically administered via a central venous catheter. Although high-dose insulin and glucose may be administered peripherally, they would likely be given through the central venous catheter if one is placed. Dosing for each of these therapies is provided below. (See <a class="local">'Specific therapies'</a> below.)</p><p class="headingAnchor" id="H61484301"><span class="h3">Mildly symptomatic patients</span><span class="headingEndMark"> — </span>Our suggested approach to patients with mild hypotension or bradycardia begins with IV boluses of isotonic crystalloid and <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a> respectively. However, these therapies often do not completely reverse the cardiotoxic effects of beta blocker poisoning. In such cases, we add the following treatments in succession based upon patient response [<a href="#rid20">20</a>]. As an example, we begin treatment with <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> if IV crystalloid does not adequately improve the patient’s blood pressure, but if hypotension resolves following treatment with glucagon, we do <strong>not</strong> proceed to IV calcium salts or any other treatment specifically for the overdose.</p><p class="bulletIndent1"><span class="glyph">●</span>IV <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a></p><p class="bulletIndent1"><span class="glyph">●</span>IV calcium salts</p><p class="bulletIndent1"><span class="glyph">●</span>IV vasopressor (eg, <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>IV high-dose insulin and glucose</p><p class="bulletIndent1"><span class="glyph">●</span>IV lipid emulsion therapy for poisoning involving lipophilic medications (eg, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a>, <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a>)</p><p></p><p>A period of 15 minutes is reasonable to determine the effectiveness of a specific therapy before proceeding to the next treatment. Dosing for each of these therapies is provided below and in the following table  (<a class="graphic graphic_table graphicRef82572" href="/d/graphic/82572.html" rel="external">table 1</a>). (See <a class="local">'Specific therapies'</a> below.)</p><p class="headingAnchor" id="H61484308"><span class="h3">Asymptomatic patients</span><span class="headingEndMark"> — </span>Many patients with an isolated beta blocker overdose remain asymptomatic and may be discharged after a period of observation, unless the overdose was intentional, involved a sustained release formulation, or there are additional clinical concerns. (See <a class="local">'Disposition'</a> below.)</p><p class="headingAnchor" id="H16"><span class="h2">Specific therapies</span><span class="headingEndMark"> — </span>Evidence supporting specific treatment interventions for beta blocker overdose is largely limited to observational studies of limited quality. A systematic review of this evidence concluded that catecholamines, high-dose insulin, and venoarterial extracorporeal membrane oxygenation were associated with reduced mortality but noted that multiple treatments were often given simultaneously, limiting the capacity to draw clear conclusions [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H17"><span class="h3">Glucagon</span><span class="headingEndMark"> — </span>Despite limited data, <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> is among the usual therapies given for beta blocker overdose [<a href="#rid21">21-23</a>]. While not an antidotal therapy, glucagon may be effective initially for a brief period, but with prolonged treatment may become ineffective due to tachyphylaxis.</p><p>Intravenous (IV) <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> is given as a slow bolus dose followed continuous infusion. An initial bolus of 5 mg intravenously is administered over one minute; if there is no increase in pulse or blood pressure after 10 to 15 minutes, a second bolus should be administered. The initial pediatric dose is 50 mcg/kg. An effect should be observed within one to three minutes, with a peak response at five to seven minutes. If there is no observed effect after 10 minutes following a second dose, it is unlikely an infusion will provide benefit.</p><p>If there is an increase in pulse or blood pressure, an infusion is started at a rate of 2 to 5 mg/hour (pediatric dose 70 mcg/kg/hour). The goal is to maintain a mean arterial pressure of 60 mmHg. If this cannot be achieved, additional therapies are implemented in a sequential manner, beginning with calcium salts. When used as a sole agent in humans, <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> has been associated with treatment failures.</p><p>Vomiting is common following administration of <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>. We suggest prophylactic or concurrent administration of a serotonin antagonist antiemetic (eg, <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a>). (See  <a class="medical medical_review" href="/d/html/2538.html" rel="external">"Characteristics of antiemetic drugs"</a>.)</p><p>In a retrospective, multicenter case series of 107 patients with suspected beta blocker poisoning, <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> administration was associated with a mean increase of 4 beats per minute (±10.6), although the clinical significance of this change is debatable [<a href="#rid23">23</a>]. </p><p><a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">Glucagon</a> activates adenylate cyclase at a site independent from beta-adrenergic agents, causing an increase in adenosine 3'-5'-cyclic monophosphate (cAMP). Elevations in cAMP increase the intracellular pool of calcium available for release during depolarization, augmenting contractility. The successful use of glucagon to manage beta blocker toxicity has been documented in many case reports, but no controlled trials involving humans have been conducted [<a href="#rid23">23</a>]. One review of the available controlled trials in animal models found that glucagon increased heart rate (HR), at least transiently, but had minimal effect on mean arterial pressure (MAP) [<a href="#rid21">21</a>].</p><p>In 2006, a trial comparing <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> with <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> in a swine model of <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> overdose found no difference in survival at four hours [<a href="#rid24">24</a>]. No difference was detected in HR, MAP, systolic BP, or cardiac output, except in the first hour, when vasopressin caused a marked increase in MAP and systolic BP. Notably, cardiac output did not improve following glucagon administration.</p><p class="headingAnchor" id="H635841841"><span class="h3">Calcium</span><span class="headingEndMark"> — </span>A number of case reports demonstrate the efficacy of IV calcium salts in treating beta blocker toxicity [<a href="#rid20">20,25-27</a>]. Either <a class="drug drug_general" data-topicid="9186" href="/d/drug information/9186.html" rel="external">calcium chloride</a> or <a class="drug drug_general" data-topicid="9190" href="/d/drug information/9190.html" rel="external">calcium gluconate</a> may be given:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9186" href="/d/drug information/9186.html" rel="external">Calcium chloride</a> – Calcium chloride, 1 g of a 10 percent solution (10 mL), is given as a slow push, and should be administered via a central venous catheter. The dose may be repeated up to a total of 3 g. The pediatric dose is 20 mg/kg (maximum dose is 1 g); up to 60 mg/kg may be given.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9190" href="/d/drug information/9190.html" rel="external">Calcium gluconate</a> – Calcium gluconate should be given if only peripheral IV access is available. The percentage of elemental calcium in calcium gluconate is one-third that of the <a class="drug drug_general" data-topicid="9186" href="/d/drug information/9186.html" rel="external">calcium chloride</a> salt, so 30 mL of a 10 percent solution should be administered as an initial dose. In children, give 60 mg/kg per dose (maximum dose is 3 g).</p><p></p><p>Clinicians must monitor serum calcium concentrations if treatment with an IV calcium salt is given. Lethal iatrogenic overdose has been reported [<a href="#rid28">28</a>].</p><p>IV calcium salts may improve hemodynamic parameters by increasing inotropy. Animal models suggest that calcium salts increase blood pressure and cardiac output, but do not increase heart rate, following combined calcium channel blocker and beta blocker overdose [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H2228489797"><span class="h3">Vasopressor (catecholamine)</span><span class="headingEndMark"> — </span>A catecholamine infusion may be added to therapy if the combination of <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a>, IV fluids, <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>, and IV calcium salts are unsuccessful in improving cardiovascular performance. Catecholamine may also be used as a temporizing measure until high dose insulin therapy starts to take effect. The vasopressor can then be titrated downward as tolerated. (See  <a class="medical medical_review" href="/d/html/1619.html" rel="external">"Use of vasopressors and inotropes"</a>.)</p><p>An infusion of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> at 1 mcg/minute can be started and titrated upwards to maintain a MAP of 60 mmHg. Pediatric dosing starts at 0.1 mcg/kg per minute and is titrated upwards based upon the patient's MAP. High infusion rates may be necessary to overcome competitive inhibition. An arterial line may be needed to monitor blood pressure.</p><p>In animal models and human case reports, treatment of beta blocker overdose with catecholamine infusion alone has resulted in poor outcomes [<a href="#rid25">25,28,29</a>]. Thus, it is used as adjunct therapy.</p><p>Catecholamines exert positive inotropic and chronotropic activity on the myocardium by stimulating adrenergic receptors and increasing the concentration of cAMP. One possible explanation for the lack of effectiveness of catecholamines in beta blocker overdose is that high doses are often required to achieve a therapeutic effect, and such doses may increase the risk of arrhythmia. In addition, some speculate that unopposed alpha constriction increases the cardiac workload, diminishing stroke volume and cardiac output.</p><p class="headingAnchor" id="H20"><span class="h3">Insulin and glucose</span><span class="headingEndMark"> — </span>In patients who manifest hemodynamic instability refractory to the other therapies described above, we suggest that a trial of high-dose insulin and glucose be administered, possibly in combination with other agents depending on the clinical scenario, and titrated upward until blood pressure stabilizes [<a href="#rid30">30,31</a>]. (See <a class="local">'Approach to the selection of specific therapies'</a> above.) </p><p>The dosing regimen for high-dose insulin is described in detail separately and provided in the following table  (<a class="graphic graphic_table graphicRef82572" href="/d/graphic/82572.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/331.html" rel="external">"Calcium channel blocker poisoning", section on 'Insulin and glucose'</a>.)</p><p>Of note, hypoglycemia is a possible complication of this treatment, as the dose of insulin is much higher (approximately 10-fold) than that typically given for diabetic ketoacidosis. When necessary, euglycemia can be maintained by means of a continuous IV infusion of 5 to 10 percent dextrose (a higher concentration can be used if necessary to reduce fluid load).</p><p>A hemodynamic response to high-dose insulin therapy is delayed for 30 to 60 minutes, therefore simultaneous implementation of other therapies to support the patient's pulse and blood pressure are generally required. Repletion of potassium and magnesium may be needed. Serum glucose, serum potassium, and fluid intake and output should all be closely monitored for the duration of treatment with high-dose insulin. We suggest measuring glucose (eg, fingerstick) every 15 to 30 minutes while titrating the insulin infusion rate, and approximately every one to two hours once a steady rate is determined and glucose measurements are stable. </p><p>Animal studies and case reports of both isolated beta blocker overdose and combined calcium channel blocker and beta blocker overdose suggest that treatment with high dose insulin and glucose is effective [<a href="#rid32">32-34</a>]. However, the role for this therapy in pure beta blocker overdose remains unsettled, despite an increasing number of case reports describing successful treatment of patients with severe beta-blocker and mixed beta-blocker overdoses [<a href="#rid35">35</a>]. Often, such cases involve patients treated with multiple therapies (eg, calcium, <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a>, <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>, vasopressors) before treatment with high dose insulin, making it difficult to determine which therapy was most effective. High dose insulin has been well tolerated in patients, and has been administered for prolonged periods, up to 116 hours in one case [<a href="#rid35">35</a>]. </p><p>One animal study of insulin therapy in <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> toxicity was terminated early when every pig in the insulin and glucose treatment group achieved the study goal of four hour survival, while those treated with <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> and <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> died within 90 minutes [<a href="#rid28">28</a>]. Cardiac output (CO) in animals treated with insulin and glucose increased steadily and consistently, while CO in animals treated with vasopressin and epinephrine decreased until death.</p><p>It appears that insulin exhibits a steady dose response curve, and may be titrated upwards until blood pressure improves. One study using a pig model of <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> overdose, compared treatments with placebo and insulin at doses of 1 unit/kg per hour, 5 units/kg per hour, and 10 units/kg per hour [<a href="#rid36">36</a>]. For each one unit/kg per hour increase of insulin, there was a statistically significant increase in cardiac output, and no ceiling effect was noted. </p><p>The pathophysiology of beta blocker intoxication is similar in many respects to that of calcium channel blocker (CCB) intoxication, for which high dose insulin and glucose therapy has been more extensively studied. Although the mechanism is not completely understood, both CCB and beta blocker poisoning appear to interfere with myocyte metabolism. In addition, beta blockers inhibit pancreatic insulin release, further reducing available glucose and diminishing CO. Insulin appears to improve inotropy by providing substrate for aerobic metabolism within the myocyte. (See  <a class="medical medical_review" href="/d/html/331.html" rel="external">"Calcium channel blocker poisoning", section on 'Pathophysiology'</a>.)</p><p class="headingAnchor" id="H8781788"><span class="h3">Lipid emulsion therapy</span><span class="headingEndMark"> — </span>Lipid emulsions are the fats used in total <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> (TPN). Initially used to treat overdoses of local anesthetics such as <a class="drug drug_general" data-topicid="9169" href="/d/drug information/9169.html" rel="external">bupivacaine</a>, intravenous lipid emulsion (ILE) has been used to treat poisonings involving other lipophilic medications and causing hemodynamic instability [<a href="#rid37">37</a>]. Lipophilic beta blockers include <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a>, and <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a>. The dosing protocol most widely reported for patients with hemodynamic instability begins with an IV bolus of 1.5 mL/kg of a 20% lipid emulsion solution delivered over one minute. If there is no response, the same dose may be repeated every three to five minutes for a total of three bolus doses.</p><p>A more complete discussion of ILE, including subsequent infusion dosing, is found separately; we suggest consultation with a medical toxicologist or poison control center to determine whether ILE therapy is appropriate [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/331.html" rel="external">"Calcium channel blocker poisoning", section on 'Lipid emulsion therapy'</a>.)</p><p>Studies of ILE therapy are preliminary and limited. ILE may have a useful role in the treatment of patients who are hemodynamically unstable from particular poisonings, including beta blockers, after more traditional therapies (eg, <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a>, <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>, high dose insulin and glucose, vasopressors) have failed to restore hemodynamic stability.</p><p>ILE has been used successfully in documented cases of severe beta blocker overdose [<a href="#rid38">38,39</a>]. Several case reports describe patients treated with both high dose insulin and ILE with good results [<a href="#rid40">40</a>]. ILE may be used early in the treatment of an overdose of a highly lipophilic agent (eg, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a>, <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a>), or as an adjunct to other treatments as described above. ILE is unlikely to be effective when treating an overdose of a non-lipophilic medication such as <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a>, which can be removed by hemodialysis. (See <a class="local">'Approach to the selection of specific therapies'</a> above and <a class="local">'Other therapies'</a> below.)</p><p class="headingAnchor" id="H22"><span class="h3">Gastrointestinal (GI) decontamination</span><span class="headingEndMark"> — </span>GI decontamination may involve activated charcoal (AC), whole bowel irrigation, or gastric lavage; therapy is based upon clinical circumstance. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient"</a>.)</p><p>We suggest treatment with activated charcoal (AC), 1 g/kg by mouth or nasogastric tube, in all patients who present within one to two hours of a known or suspected beta blocker ingestion, unless there are contraindications to its administration. Charcoal should be withheld in patients who are sedated and may not be able to protect their airway, unless endotracheal intubation is performed first. However, endotracheal intubation should not be performed solely for the purpose of giving charcoal.</p><p>Asymptomatic patients who present more than two hours after a reported ingestion are unlikely to benefit from AC, and we do not recommend routine treatment in these patients.</p><p>The role of activated charcoal in symptomatic patients who present several hours after ingestion is more controversial. We suggest the administration of AC (1 g/kg by mouth or nasogastric tube) if there are no contraindications to charcoal administration. Although there are no data to suggest improved outcomes with AC in such patients, we believe that AC is a relatively safe intervention whose potential benefits in this situation outweigh its risks.</p><p>Gastric lavage should not be routinely performed, but may be considered for patients who present within one hour following ingestion of a large quantity of medication. Large sustained or controlled release tablets may not pass through the oral gastric tube.</p><p>Whole bowel irrigation is reserved for patients who have ingested sustained release or enteric coated preparations, or have suspected drug concretions (pharmacobezoars) in the GI tract.</p><p class="headingAnchor" id="H23"><span class="h3">Other therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">Sodium bicarbonate</a> – Sodium bicarbonate has been used successfully in the treatment of beta blocker induced arrhythmia [<a href="#rid41">41,42</a>]. Because it is a relatively safe intervention, we suggest giving it as an adjunct for patients with QRS widening.</p><p></p><p class="bulletIndent1">The dose of <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> is 1 to 2 mEq/kg given as an IV push, which may be repeated. If treatment is effective, an infusion can be started. We mix 132 mEq of sodium bicarbonate in 1 L of D5W and infuse at 250 mL/hour in adults, and at twice the maintenance fluid rate in children. The infusion is tapered once the arrhythmia resolves. (See  <a class="medical medical_review" href="/d/html/295.html" rel="external">"Tricyclic antidepressant poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Magnesium</strong> – Magnesium may be administered when ventricular arrhythmias are present or hypomagnesemia is suspected. <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">Sotalol</a> has a high propensity to induce ventricular arrhythmias and will often require magnesium, administered as a 2 g IV bolus or as a continuous infusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IV cardiac pacing</strong> – Ventricular pacing may be effective in patients with profound bradycardia, or in patients with combined beta blocker and calcium channel blocker intoxication [<a href="#rid43">43</a>]. However, ventricular pacing frequently fails to capture, or increases the heart rate without a corresponding increase in perfusion [<a href="#rid44">44</a>]. IV pacing can be implemented if there is no response to pharmacologic therapies, and the patient remains bradycardic and hypotensive. Some authors note a decrease in blood pressure with pacing [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/1005.html" rel="external">"Temporary cardiac pacing"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intraaortic balloon pump</strong> – The intraaortic balloon pump has been used successfully after failure of pharmacologic management in severe cases of <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> and <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a> overdose [<a href="#rid45">45,46</a>] and in combined verapamil-SR (sustained release) and atenolol overdose [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/d/html/1482.html" rel="external">"Intraaortic balloon pump counterpulsation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodialysis and alternative renal replacement treatment</strong> – Hemodialysis has a minimal role in the treatment of beta blocker overdose and is effective only with hydrophilic, minimally protein-bound beta blockers such as <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a> [<a href="#rid48">48</a>]. <a class="drug drug_general" data-topicid="9672" href="/d/drug information/9672.html" rel="external">Nadolol</a>, <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">sotalol</a>, <a class="drug drug_general" data-topicid="9233" href="/d/drug information/9233.html" rel="external">acebutolol</a>, and atenolol are reportedly removed by hemodialysis, but <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a>, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, and <a class="drug drug_general" data-topicid="9997" href="/d/drug information/9997.html" rel="external">timolol</a> are not.</p><p></p><p class="bulletIndent1">Hemodialysis is reserved for patients who have not improved despite aggressive medical intervention, have ingested a significant amount of a beta blocker that can be removed using dialysis (eg, <a class="drug drug_general" data-topicid="9233" href="/d/drug information/9233.html" rel="external">acebutolol</a>), or have ingested other cardioactive medications that may exacerbate toxicity. In such cases, the emergency clinician should contact a nephrologist early in the patient's course to avoid delays in preparing for hemodialysis.</p><p></p><p class="bulletIndent1">Continuous venovenous hemodialysis (VVHD) can be used if the patient is not able to tolerate traditional hemodialysis due to pronounced hypotension. The decision to initiate hemodialysis and the selection of the appropriate type is made in consultation with the nephrologist. (See  <a class="medical medical_review" href="/d/html/325.html" rel="external">"Enhanced elimination of poisons"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extracorporeal membrane oxygenation</strong> – Extracorporeal membrane oxygenation has been used in severe life-threatening ingestions with some reports of successful recovery [<a href="#rid49">49</a>]. This intervention should be reserved for patients with severe ingestions who do not respond to standard therapy.</p><p></p><p class="headingAnchor" id="H24"><span class="h2">Pediatric considerations</span><span class="headingEndMark"> — </span>Although hypoglycemia is seen more often in pediatric patients than adults, overall management does not differ significantly in children. Children may be more susceptible to direct central nervous system toxicity.</p><p>We recommend 24 hours of observation in a monitored setting for any initially asymptomatic child who has ingested an extended release preparation, <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">sotalol</a>, or multiple cardioactive agents. Outside of such cases, the great majority of isolated ingestions by young children are uneventful and they can be discharged after a six hour period of observation [<a href="#rid50">50-52</a>].</p><p>Children may be observed safely at home after the witnessed ingestion of a single beta blocker tablet and Poison Control Centers typically manage these exposures via telephone follow-up [<a href="#rid53">53,54</a>]. Should the patient's family call the Emergency Department (ED) for advice, it is prudent to advise them to bring the child to the ED for evaluation since follow-up can be problematic.</p><p class="headingAnchor" id="H25"><span class="h2">Disposition</span><span class="headingEndMark"> — </span>Patients who have ingested a beta blocker and who manifest hemodynamic instability or an altered mental status should be admitted to a critical care unit for cardiac monitoring and further management.</p><p><a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">Sotalol</a> has a long half-life and toxicity may result in ventricular dysrhythmias. Thus, patients require 24 hours of inpatient cardiac monitoring following sotalol overdose, even if they are asymptomatic.</p><p>Any person who has taken an overdose of a beta blocker with membrane stabilizing activity  (<a class="graphic graphic_table graphicRef82571" href="/d/graphic/82571.html" rel="external">table 2</a>) or multiple cardioactive medications is at increased risk of severe toxicity and should be observed in the emergency department for six hours. Patients who remain asymptomatic without need of intervention can be safely discharged. Patients who are asymptomatic at presentation after ingestion of a sustained release beta blocker should be observed for at least six hours to insure that symptoms do not develop [<a href="#rid6">6</a>].</p><p>Asymptomatic adults who have inadvertently ingested an amount of beta blocking agent no greater than their total daily dose (excluding <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">sotalol</a>) may be observed safely at home [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H26"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H705215399"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H1464691540"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course and table for emergency management</strong> – Although beta blocker overdose generally follows a benign clinical course, patients with significant toxicity require aggressive medical management. A summary table to facilitate emergency management is provided  (<a class="graphic graphic_table graphicRef82572" href="/d/graphic/82572.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug characteristics associated with increased toxicity</strong> – Toxicity increases greatly when an agent has membrane stabilizing activity (MSA)  (<a class="graphic graphic_table graphicRef82571" href="/d/graphic/82571.html" rel="external">table 2</a>) or when other cardioactive agents are ingested concomitantly. Lipophilic agents cross the blood brain barrier and can cause neurologic dysfunction even in the absence of systemic hypotension  (<a class="graphic graphic_table graphicRef82571" href="/d/graphic/82571.html" rel="external">table 2</a>). (See <a class="local">'Cellular toxicology'</a> above and <a class="local">'Toxicity of general class and specific drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity of specific drugs</strong> – <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">Sotalol</a> is a unique agent with an extended half-life that can cause QTc interval prolongation and severe ventricular arrhythmias in overdose. <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">Propranolol</a> and <a class="drug drug_general" data-topicid="9233" href="/d/drug information/9233.html" rel="external">acebutolol</a> possess properties that increase their potential toxicity. (See <a class="local">'Toxicity of general class and specific drugs'</a> above and <a class="local">'History'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Most patients who develop toxicity from beta blocker overdose do so within two hours of ingestion, and virtually all do so within six hours. Bradycardia and hypotension are the most common effects. Cardiogenic shock and ventricular dysrhythmias can occur with severe overdose. Other potential effects of severe toxicity include mental status change, seizure, hypoglycemia, and bronchospasm. Hypoglycemia is seen more often in children. (See <a class="local">'Physical findings'</a> above and <a class="local">'Pediatric considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic studies</strong> – The following studies should be obtained: an electrocardiogram (ECG), a fingerstick glucose, serum electrolytes including calcium, and blood urea nitrogen and creatinine concentrations. Cardiac conduction delays can occur, most often a prolonged PR interval. In severe poisoning, <strong>any</strong> bradydysrhythmia can develop, and may progress to asystole. (See <a class="local">'Laboratory studies'</a> above and <a class="local">'Electrocardiogram'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of severe poisoning</strong> – For patients with severely symptomatic poisoning (eg, profound persistent hypotension or bradycardia), we suggest simultaneous treatment with <strong>all</strong> of the therapies listed (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Dosing is provided in the text and the rapid overview table  (<a class="graphic graphic_table graphicRef82572" href="/d/graphic/82572.html" rel="external">table 1</a>). Severe beta blocker poisoning can be difficult to manage and consultation with a medical toxicologist or regional poison control center is highly encouraged (see <a class="local">'Acute stabilization and overview of therapy'</a> above and <a class="local">'Severely symptomatic patients'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stabilization of the airway as necessary (avoid induction agents that exacerbate hypotension)</p><p class="bulletIndent2"><span class="glyph">•</span>Additional intravenous (IV) boluses of isotonic crystalloid</p><p class="bulletIndent2"><span class="glyph">•</span>IV <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a></p><p class="bulletIndent2"><span class="glyph">•</span>IV calcium salts</p><p class="bulletIndent2"><span class="glyph">•</span>Vasopressor (eg, <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>IV high-dose insulin and glucose</p><p class="bulletIndent2"><span class="glyph">•</span>IV lipid emulsion therapy for poisoning involving lipophilic medications (eg, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a>, <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of non-severe poisoning</strong> – For patients who are mildly symptomatic, and in whom IV fluids, <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a>, and <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> prove ineffective at reversing signs of cardiotoxicity, we suggest a stepwise treatment approach (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We give the following treatments, in succession, based upon patient response: IV calcium salts, lipid emulsion therapy, vasopressors, and high-dose insulin and glucose. The implementation of each therapeutic option is discussed in the text. (See <a class="local">'Acute stabilization and overview of therapy'</a> above and <a class="local">'Specific therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional treatments including hemodialysis</strong> – <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">Sodium bicarbonate</a> and magnesium may be needed to treat some arrhythmias. Hemodialysis may rarely be needed, in which case a nephrologist should be contacted early. (See <a class="local">'Other therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disposition</strong> – The length of observation following inadvertent overdose varies according to the type and number of medications ingested. (See <a class="local">'Disposition'</a> above.)</p><p></p><p class="headingAnchor" id="H574141573"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Ellen Lemkin, MD, PharmD, who contributed to an earlier version of this topic review.</p><p>The UpToDate editorial staff acknowledges Stephen J Traub, MD, former section editor of the toxicology program, for 20 years of dedicated service.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol (Phila) 2007; 45:815.</a></li><li><a class="nounderline abstract_t">Correia MS, Whitehead E, Cantrell FL, et al. A 10-year review of single medication double-dose ingestions in the nation's largest poison control system. Clin Toxicol (Phila) 2019; 57:31.</a></li><li><a class="nounderline abstract_t">Vucinić S, Joksović D, Jovanović D, et al. Factors influencing the degree and outcome of acute beta-blockers poisoning. Vojnosanit Pregl 2000; 57:619.</a></li><li><a class="nounderline abstract_t">Taboulet P, Cariou A, Berdeaux A, Bismuth C. Pathophysiology and management of self-poisoning with beta-blockers. J Toxicol Clin Toxicol 1993; 31:531.</a></li><li><a class="nounderline abstract_t">Samuels TL, Uncles DR, Willers JW, et al. Logging the potential for intravenous lipid emulsion in propranolol and other lipophilic drug overdoses. Anaesthesia 2011; 66:221.</a></li><li><a class="nounderline abstract_t">Love JN, Howell JM, Litovitz TL, Klein-Schwartz W. Acute beta blocker overdose: factors associated with the development of cardiovascular morbidity. J Toxicol Clin Toxicol 2000; 38:275.</a></li><li><a class="nounderline abstract_t">Love JN. Acebutolol overdose resulting in fatalities. J Emerg Med 2000; 18:341.</a></li><li><a class="nounderline abstract_t">Link MS, Foote CB, Sloan SB, et al. Torsade de pointes and prolonged QT interval from surreptitious use of sotalol: use of drug levels in diagnosis. Chest 1997; 112:556.</a></li><li><a class="nounderline abstract_t">Vlahovic-Palcevski V, Milic S, Hauser G, et al. Toxic epidermal necrolysis associated with carvedilol treatment. Int J Clin Pharmacol Ther 2010; 48:549.</a></li><li><a class="nounderline abstract_t">Reith DM, Dawson AH, Epid D, et al. Relative toxicity of beta blockers in overdose. J Toxicol Clin Toxicol 1996; 34:273.</a></li><li><a class="nounderline abstract_t">Neuvonen PJ, Elonen E, Vuorenmaa T, Laakso M. Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication. Eur J Clin Pharmacol 1981; 20:85.</a></li><li><a class="nounderline abstract_t">Love JN, Litovitz TL, Howell JM, Clancy C. Characterization of fatal beta blocker ingestion: a review of the American Association of Poison Control Centers data from 1985 to 1995. J Toxicol Clin Toxicol 1997; 35:353.</a></li><li><a class="nounderline abstract_t">Lifshitz M, Zucker N, Zalzstein E. Acute dilated cardiomyopathy and central nervous system toxicity following propranolol intoxication. Pediatr Emerg Care 1999; 15:262.</a></li><li><a class="nounderline abstract_t">Mégarbane B, Deye N, Malissin I, Baud FJ. Usefulness of the serum lactate concentration for predicting mortality in acute beta-blocker poisoning. Clin Toxicol (Phila) 2010; 48:974.</a></li><li><a class="nounderline abstract_t">Love JN, Enlow B, Howell JM, et al. Electrocardiographic changes associated with beta-blocker toxicity. Ann Emerg Med 2002; 40:603.</a></li><li><a class="nounderline abstract_t">Rennyson SL, Littmann L. Brugada-pattern electrocardiogram in propranolol intoxication. Am J Emerg Med 2010; 28:256.e7.</a></li><li><a class="nounderline abstract_t">Soni N, Baines D, Pearson IY. Cardiovascular collapse and propranolol overdose. Med J Aust 1983; 2:629.</a></li><li><a class="nounderline abstract_t">Hofer CA, Smith JK, Tenholder MF. Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options. Am J Med 1993; 95:431.</a></li><li><a class="nounderline abstract_t">Ashraf M, Chaudhary K, Nelson J, Thompson W. Massive overdose of sustained-release verapamil: a case report and review of literature. Am J Med Sci 1995; 310:258.</a></li><li><a class="nounderline abstract_t">Rotella JA, Greene SL, Koutsogiannis Z, et al. Treatment for beta-blocker poisoning: a systematic review. Clin Toxicol (Phila) 2020; 58:943.</a></li><li><a class="nounderline abstract_t">Bailey B. Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. J Toxicol Clin Toxicol 2003; 41:595.</a></li><li><a class="nounderline abstract_t">Boyd R, Ghosh A. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Glucagon for the treatment of symptomatic beta blocker overdose. Emerg Med J 2003; 20:266.</a></li><li><a class="nounderline abstract_t">Senart AM, LeClair LA. Cardiovascular and Adverse Effects of Glucagon for the Management of Suspected Beta Blocker Toxicity: a Case Series. J Med Toxicol 2023; 19:9.</a></li><li><a class="nounderline abstract_t">Holger JS, Engebretsen KM, Obetz CL, et al. A comparison of vasopressin and glucagon in beta-blocker induced toxicity. Clin Toxicol (Phila) 2006; 44:45.</a></li><li><a class="nounderline abstract_t">Pertoldi F, D'Orlando L, Mercante WP. Electromechanical dissociation 48 hours after atenolol overdose: usefulness of calcium chloride. Ann Emerg Med 1998; 31:777.</a></li><li><a class="nounderline abstract_t">Brimacombe JR, Scully M, Swainston R. Propranolol overdose--a dramatic response to calcium chloride. Med J Aust 1991; 155:267.</a></li><li><a class="nounderline abstract_t">Henry M, Kay MM, Viccellio P. Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride. Am J Emerg Med 1985; 3:334.</a></li><li><a class="nounderline abstract_t">Holger JS, Engebretsen KM, Fritzlar SJ, et al. Insulin versus vasopressin and epinephrine to treat beta-blocker toxicity. Clin Toxicol (Phila) 2007; 45:396.</a></li><li><a class="nounderline abstract_t">Avery GJ 2nd, Spotnitz HM, Rose EA, et al. Pharmacologic antagonism of beta-adrenergic blockade in dogs. I. Hemodynamic effects of isoproterenol, dopamine, and epinephrine in acute propranolol administration. J Thorac Cardiovasc Surg 1979; 77:267.</a></li><li><a class="nounderline abstract_t">Krenz JR, Kaakeh Y. An Overview of Hyperinsulinemic-Euglycemic Therapy in Calcium Channel Blocker and β-blocker Overdose. Pharmacotherapy 2018; 38:1130.</a></li><li><a class="nounderline abstract_t">Cole JB, Arens AM, Laes JR, et al. High dose insulin for beta-blocker and calcium channel-blocker poisoning. Am J Emerg Med 2018; 36:1817.</a></li><li><a class="nounderline abstract_t">Kerns W 2nd, Schroeder D, Williams C, et al. Insulin improves survival in a canine model of acute beta-blocker toxicity. Ann Emerg Med 1997; 29:748.</a></li><li><a class="nounderline abstract_t">Burns MJ, Linden CH. Insulin for beta-blocker toxicity. Ann Emerg Med 1997; 30:711.</a></li><li><a class="nounderline abstract_t">Page C, Hacket LP, Isbister GK. The use of high-dose insulin-glucose euglycemia in beta-blocker overdose: a case report. J Med Toxicol 2009; 5:139.</a></li><li class="breakAll">Lyden AE, Cooper C, Park E. Beta-Blocker Overdose Treated with Extended Duration High Dose Insulin Therapy. J Pharmacol ClinToxicol 2014; 2:1015. http://www.jscimedcentral.com/Pharmacology/pharmacology-2-1015.pdf (Accessed on June 16, 2014).</li><li><a class="nounderline abstract_t">Cole JB, Stellpflug SJ, Ellsworth H, et al. A blinded, randomized, controlled trial of three doses of high-dose insulin in poison-induced cardiogenic shock. Clin Toxicol (Phila) 2013; 51:201.</a></li><li><a class="nounderline abstract_t">Gosselin S, Hoegberg LC, Hoffman RS, et al. Evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning(). Clin Toxicol (Phila) 2016; 54:899.</a></li><li><a class="nounderline abstract_t">Jovic-Stosic J, Gligic B, Putic V, et al. Severe propranolol and ethanol overdose with wide complex tachycardia treated with intravenous lipid emulsion: a case report. Clin Toxicol (Phila) 2011; 49:426.</a></li><li><a class="nounderline abstract_t">Stellpflug SJ, Harris CR, Engebretsen KM, et al. Intentional overdose with cardiac arrest treated with intravenous fat emulsion and high-dose insulin. Clin Toxicol (Phila) 2010; 48:227.</a></li><li><a class="nounderline abstract_t">Doepker B, Healy W, Cortez E, Adkins EJ. High-dose insulin and intravenous lipid emulsion therapy for cardiogenic shock induced by intentional calcium-channel blocker and Beta-blocker overdose: a case series. J Emerg Med 2014; 46:486.</a></li><li><a class="nounderline abstract_t">Donovan KD, Gerace RV, Dreyer JF. Acebutolol-induced ventricular tachycardia reversed with sodium bicarbonate. J Toxicol Clin Toxicol 1999; 37:481.</a></li><li><a class="nounderline abstract_t">Shanker UR, Webb J, Kotze A. Sodium bicarbonate to treat massive beta blocker overdose. Emerg Med J 2003; 20:393.</a></li><li><a class="nounderline abstract_t">Snook CP, Sigvaldason K, Kristinsson J. Severe atenolol and diltiazem overdose. J Toxicol Clin Toxicol 2000; 38:661.</a></li><li><a class="nounderline abstract_t">Hurwitz MD, Kallenbach JM, Pincus PS. Massive propranolol overdose. Am J Med 1986; 81:1118.</a></li><li><a class="nounderline abstract_t">Kulling P, Eleborg L, Persson H. Beta-adrenoceptor blocker intoxication: epidemiological data. Prenalterol as an alternative in the treatment of cardiac dysfunction. Hum Toxicol 1983; 2:175.</a></li><li><a class="nounderline abstract_t">Lane AS, Woodward AC, Goldman MR. Massive propranolol overdose poorly responsive to pharmacologic therapy: use of the intra-aortic balloon pump. Ann Emerg Med 1987; 16:1381.</a></li><li><a class="nounderline abstract_t">Frierson J, Bailly D, Shultz T, et al. Refractory cardiogenic shock and complete heart block after unsuspected verapamil-SR and atenolol overdose. Clin Cardiol 1991; 14:933.</a></li><li><a class="nounderline abstract_t">Bouchard J, Shepherd G, Hoffman RS, et al. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. Crit Care 2021; 25:201.</a></li><li><a class="nounderline abstract_t">Nordmark Grass J, Ahlner J, Kugelberg FC, et al. A case of massive metoprolol and amlodipine overdose with blood concentrations and survival following extracorporeal corporeal membrane oxygenation (ECMO). Clin Toxicol (Phila) 2019; 57:66.</a></li><li><a class="nounderline abstract_t">Love JN, Howell JM, Klein-Schwartz W, Litovitz TL. Lack of toxicity from pediatric beta-blocker exposures. Hum Exp Toxicol 2006; 25:341.</a></li><li><a class="nounderline abstract_t">Belson MG, Sullivan K, Geller RJ. Beta-adrenergic antagonist exposures in children. Vet Hum Toxicol 2001; 43:361.</a></li><li><a class="nounderline abstract_t">Watson CJ, Monuteaux MC, Burns MM. Characterization of pediatric beta-adrenergic antagonist ingestions reported to the National Poison Data System from 2000 to 2020. Acad Emerg Med 2023; 30:1129.</a></li><li><a class="nounderline abstract_t">Love JN, Sikka N. Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers. J Emerg Med 2004; 26:309.</a></li><li><a class="nounderline abstract_t">Wax PM, Erdman AR, Chyka PA, et al. beta-blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2005; 43:131.</a></li></ol></div><div id="topicVersionRevision">Topic 330 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18163234" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30484705" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A 10-year review of single medication double-dose ingestions in the nation's largest poison control system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11332352" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Factors influencing the degree and outcome of acute beta-blockers poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7902873" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pathophysiology and management of self-poisoning with beta-blockers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21320091" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Logging the potential for intravenous lipid emulsion in propranolol and other lipophilic drug overdoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10866327" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Acute beta blocker overdose: factors associated with the development of cardiovascular morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10729673" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acebutolol overdose resulting in fatalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9266902" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Torsade de pointes and prolonged QT interval from surreptitious use of sotalol: use of drug levels in diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20650047" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Toxic epidermal necrolysis associated with carvedilol treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8667464" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Relative toxicity of beta blockers in overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7262178" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9204094" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Characterization of fatal beta blocker ingestion: a review of the American Association of Poison Control Centers data from 1985 to 1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10460081" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acute dilated cardiomyopathy and central nervous system toxicity following propranolol intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21192755" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Usefulness of the serum lactate concentration for predicting mortality in acute beta-blocker poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12447337" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Electrocardiographic changes associated with beta-blocker toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159410" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Brugada-pattern electrocardiogram in propranolol intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6669127" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cardiovascular collapse and propranolol overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8213877" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503108" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Massive overdose of sustained-release verapamil: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32310006" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treatment for beta-blocker poisoning: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514004" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12748150" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Glucagon for the treatment of symptomatic beta blocker overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36479689" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cardiovascular and Adverse Effects of Glucagon for the Management of Suspected Beta Blocker Toxicity: a Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16496493" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A comparison of vasopressin and glucagon in beta-blocker induced toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9624322" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Electromechanical dissociation 48 hours after atenolol overdose: usefulness of calcium chloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1875846" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Propranolol overdose--a dramatic response to calcium chloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2860911" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17486481" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Insulin versus vasopressin and epinephrine to treat beta-blocker toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33298" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pharmacologic antagonism of beta-adrenergic blockade in dogs. I. Hemodynamic effects of isoproterenol, dopamine, and epinephrine in acute propranolol administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30141827" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : An Overview of Hyperinsulinemic-Euglycemic Therapy in Calcium Channel Blocker andβ-blocker Overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29452919" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : High dose insulin for beta-blocker and calcium channel-blocker poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9174520" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Insulin improves survival in a canine model of acute beta-blocker toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9360589" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Insulin for beta-blocker toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19655287" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The use of high-dose insulin-glucose euglycemia in beta-blocker overdose: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19655287" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The use of high-dose insulin-glucose euglycemia in beta-blocker overdose: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23530460" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A blinded, randomized, controlled trial of three doses of high-dose insulin in poison-induced cardiogenic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27608281" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning().</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21740142" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Severe propranolol and ethanol overdose with wide complex tachycardia treated with intravenous lipid emulsion: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20141425" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intentional overdose with cardiac arrest treated with intravenous fat emulsion and high-dose insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24530120" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : High-dose insulin and intravenous lipid emulsion therapy for cardiogenic shock induced by intentional calcium-channel blocker and Beta-blocker overdose: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10465245" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Acebutolol-induced ventricular tachycardia reversed with sodium bicarbonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12835373" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sodium bicarbonate to treat massive beta blocker overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11185975" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Severe atenolol and diltiazem overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3799650" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Massive propranolol overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6134663" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Beta-adrenoceptor blocker intoxication: epidemiological data. Prenalterol as an alternative in the treatment of cardiac dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3688604" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Massive propranolol overdose poorly responsive to pharmacologic therapy: use of the intra-aortic balloon pump.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1764831" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Refractory cardiogenic shock and complete heart block after unsuspected verapamil-SR and atenolol overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34112223" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30004266" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A case of massive metoprolol and amlodipine overdose with blood concentrations and survival following extracorporeal corporeal membrane oxygenation (ECMO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16866192" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Lack of toxicity from pediatric beta-blocker exposures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11757997" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Beta-adrenergic antagonist exposures in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37350748" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Characterization of pediatric beta-adrenergic antagonist ingestions reported to the National Poison Data System from 2000 to 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028329" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15906457" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : beta-blocker ingestion: an evidence-based consensus guideline for out-of-hospital management.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
